IQVIA (NYSE:IQV) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of IQVIA (NYSE:IQVGet Rating) from a hold rating to a buy rating in a research report released on Tuesday morning.

IQV has been the subject of several other reports. William Blair reiterated an outperform rating on shares of IQVIA in a report on Wednesday, February 16th. Wells Fargo & Company lowered IQVIA from an overweight rating to an equal weight rating and cut their price objective for the stock from $290.00 to $235.00 in a report on Monday, April 25th. Barclays cut their price objective on IQVIA from $275.00 to $240.00 in a report on Thursday, April 28th. Piper Sandler raised shares of IQVIA from a neutral rating to an overweight rating and increased their target price for the stock from $231.00 to $255.00 in a research report on Thursday, April 28th. Finally, Mizuho lowered their target price on shares of IQVIA from $300.00 to $270.00 and set a buy rating on the stock in a research report on Monday, March 7th. Two equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, IQVIA has a consensus rating of Buy and an average price target of $279.47.

IQV opened at $208.71 on Tuesday. The stock has a fifty day moving average of $224.94 and a 200-day moving average of $243.86. The firm has a market capitalization of $39.50 billion, a P/E ratio of 37.61, a PEG ratio of 1.45 and a beta of 1.41. IQVIA has a 12-month low of $198.11 and a 12-month high of $285.61. The company has a quick ratio of 0.93, a current ratio of 0.93 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQVGet Rating) last released its earnings results on Wednesday, April 27th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.07. The company had revenue of $3.57 billion during the quarter, compared to analyst estimates of $3.54 billion. IQVIA had a return on equity of 28.80% and a net margin of 7.69%. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.05 earnings per share. On average, analysts expect that IQVIA will post 9.49 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. Riverview Trust Co acquired a new stake in IQVIA during the first quarter worth about $25,000. UMB Bank N A MO acquired a new stake in IQVIA during the fourth quarter worth about $26,000. Dividend Assets Capital LLC acquired a new stake in IQVIA during the first quarter worth about $27,000. Johnson Financial Group Inc. acquired a new stake in IQVIA during the fourth quarter worth about $34,000. Finally, Quent Capital LLC grew its position in IQVIA by 271.8% during the first quarter. Quent Capital LLC now owns 145 shares of the medical research company’s stock worth $34,000 after buying an additional 106 shares in the last quarter. 87.12% of the stock is currently owned by institutional investors.

About IQVIA (Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More

Analyst Recommendations for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.